$90 B

GILD Mkt cap, 04-Dec-2018

$5.6 B

Gilead Sciences Revenue Q3, 2018
Gilead Sciences Gross profit (Q3, 2018)4.5 B
Gilead Sciences Gross profit margin (Q3, 2018), %80.6%
Gilead Sciences Net income (Q3, 2018)2.1 B
Gilead Sciences EBIT (Q3, 2018)2.6 B
Gilead Sciences Cash, 30-Sep-201814.6 B
Gilead Sciences EV100 B

Gilead Sciences Revenue

Gilead Sciences revenue was $26.11 b in FY, 2017

Embed Graph

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by geographic segment: 20.9% from Europe, 63.7% from United States, 8.3% from Japan and 7.1% from Other

Gilead Sciences Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.2b24.9b32.6b30.4b26.1b

Revenue growth, %

122%31%(7%)

Cost of goods sold

2.9b3.8b4.0b4.3b4.4b

Gross profit

8.3b21.1b28.6b26.1b21.7b

Gross profit Margin, %

74%85%88%86%83%

R&D expense

3.7b

General and administrative expense

3.9b

Operating expense total

12.0b

EBIT

4.5b15.3b22.2b17.6b14.1b

EBIT margin, %

40%61%68%58%54%

Interest expense

306.9m412.0m688.0m964.0m1.1b

Pre tax profit

4.2b14.9b21.7b17.1b13.5b

Income tax expense

1.2b2.8b3.6b3.6b8.9b

Net Income

3.1b12.1b18.1b13.5b4.6b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018

Revenue

2.8b5.0b6.5b6.0b7.6b8.2b8.3b7.8b7.8b7.5b6.5b7.1b6.5b5.1b5.6b

Cost of goods sold

681.9m813.2m924.7m987.3m882.0m998.0m1.1b1.2b864.0m1.1b957.0m1.1b1.0b1.0b1.1b

Gross profit

2.1b4.2b5.6b5.1b6.7b7.2b7.2b6.6b6.9b6.4b5.5b6.0b5.5b4.1b4.5b

Gross profit Margin, %

75%84%86%84%88%88%87%85%89%85%85%84%84%80%81%

R&D expense

546.2m595.0m583.9m630.5m696.0m818.0m743.0m1.3b1.5b1.1b931.0m864.0m789.0m937.0m939.0m

General and administrative expense

406.9m548.1m613.6m944.8m645.0m812.0m903.0m685.0m890.0m831.0m850.0m897.0m879.0m997.0m948.0m

Operating expense total

1.6b2.0b2.1b2.6b2.2b2.6b2.7b3.1b3.2b3.1b2.7b2.9b2.7b2.9b3.0b

EBIT

1.1b3.0b4.4b3.5b5.4b5.6b5.6b4.7b4.5b4.4b3.8b4.3b3.8b2.2b2.6b

EBIT margin, %

41%61%68%58%71%68%67%60%58%59%58%60%59%42%47%

Interest expense

73.9m76.3m102.0m103.4m153.0m140.0m165.0m230.0m227.0m242.0m261.0m269.0m291.0m290.0m264.0m

Pre tax profit

1.1b2.9b4.3b3.4b5.2b5.5b5.5b4.5b4.4b4.3b3.6b4.1b3.7b2.0b2.7b

Income tax expense

294.5m725.9m656.6m646.6m907.0m1.0b880.0m935.0m902.0m951.0m918.0m1.0b959.0m494.0m565.0m

Net Income

785.2m2.2b3.7b2.7b4.3b4.5b4.6b3.6b3.5b3.3b2.7b3.1b2.7b1.5b2.1b

Gilead Sciences Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.1b10.0b12.9b8.2b7.6b

Inventories

2.1b1.4b2.0b1.6b801.0m

Current Assets

7.3b17.7b24.8b20.4b31.8b

PP&E

1.2b1.7b2.3b2.9b3.3b

Goodwill

1.2b1.2b1.2b1.2b4.2b

Total Assets

22.5b34.7b51.8b57.0b70.3b

Accounts Payable

1.3b955.0m1.2b1.2b814.0m

Short-term debt

2.7b483.0m982.0m

Current Liabilities

6.3b5.8b9.9b9.2b11.6b

Long-term debt

3.9b11.9b21.1b26.3b30.8b

Total Debt

6.6b12.4b22.1b26.3b30.8b

Additional Paid-in Capital

5.4b2.4b444.0m454.0m1.3b

Retained Earnings

6.1b12.7b18.0b18.2b19.0b

Total Equity

11.7b15.8b19.1b19.4b20.5b

Debt to Equity Ratio

0.6 x0.8 x1.2 x1.4 x1.5 x

Debt to Assets Ratio

0.3 x0.4 x0.4 x0.5 x0.4 x

Financial Leverage

1.9 x2.2 x2.7 x2.9 x3.4 x

Gilead Sciences Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.1b12.1b18.1b13.5b4.6b

Depreciation and Amortization

233.0m

Accounts Receivable

(315.3m)(2.6b)(1.4b)1.2b754.0m

Inventories

(343.1m)143.0m(855.0m)(488.0m)(253.0m)

Accounts Payable

(97.7m)(289.0m)226.0m47.0m(430.0m)

Cash From Operating Activities

3.1b12.8b20.3b16.7b11.9b

Cash From Investing Activities

(254.4m)(1.8b)(12.5b)(12.0b)(16.1b)

Cash From Financing Activities

(2.5b)(3.0b)(5.0b)(9.3b)3.4b

Interest Paid

238.3m330.0m529.0m885.0m1.0b

Income Taxes Paid

1.1b2.1b3.1b2.4b3.3b

Free Cash Flow

3.3b13.4b21.1b17.4b11.3b

Gilead Sciences Ratios

USDY, 2018

EV/EBIT

38.1 x

EV/CFO

16.5 x

EV/FCF

18.6 x

Debt/Equity

1.1 x

Debt/Assets

0.4 x

Financial Leverage

2.8 x
Report incorrect company information

Gilead Sciences Operating Metrics

FY, 2016

Countries

30

Facilities

5

Phase I Trials Products

3

Phase II Trials Products

12

Phase III Trials Products

6

Products

25
Report incorrect company information

Gilead Sciences Employee Rating

3.2760 votes
Culture & Values
3.0
Work/Life Balance
2.6
Senior Management
2.8
Salary & Benefits
3.8
Career Opportunities
2.9
Source